Drugs / Insulin Peglispro
Insulin Peglispro
English name insulin peglispro
Protein / enzyme biologic targets INSR via activation
Trials 25
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT02197520 | Jul 2014 → Jun 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02152384 | Jun → Dec 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02109029 | Apr 2014 → Mar 2015 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01995526 | Dec 2013 → Jan 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01925989 | Nov 2013 → Oct 2015 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01771250 | Oct 2013 → Dec 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01871493 | Jun → Sep 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01877265 | Jun → Sep 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01818245 | Mar → Jul 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01784211 | Feb → Nov 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01769404 | Feb → Dec 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01751399 | Dec 2012 → Sep 2013 | liver disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01654380 | Jul 2012 → Oct 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT01049412 | Jan → Dec 2010 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT01027871 | Jan → Dec 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Missed primary |
| Phase 310 trials · 2 met primary | ||||||
| Phase 3 | NCT02106364 | Feb → Nov 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 3 | NCT02132637 | May 2014 → Jul 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01894568 | Jul 2013 → Apr 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT01790438 | Mar 2013 → May 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01792284 | Feb 2013 → Apr 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01582451 | May 2012 → May 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT01454284 | Jan 2012 → Feb 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01481779 | Jan 2012 → May 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01468987 | Dec 2011 → Aug 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01435616 | Nov 2011 → Jan 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2015-06-06 | Eli Lilly and Company | Results Lilly's Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes lilly.com ↗
Eli Lilly and Company's (NYSE: LLY) basal insulin peglispro (BIL) consistently demonstrated superior hemoglobin A1c (HbA1c) reduction in people with type 2 diabetes compared to insulin glargine across three Phase III trials. |
| 2015-06-06 | Eli Lilly and Company | Results Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes lilly.com ↗
In IMAGINE-1 and IMAGINE-3, BIL demonstrated superiority in HbA1c compared to insulin glargine. |
| 2015-05-27 | Eli Lilly and Company | Results Lilly to Present New Clinical Data at 75th American Diabetes Association® Scientific Sessions lilly.com ↗
Basal Insulin Peglispro (BIL) is Superior to Insulin Glargine (GL) in Reducing HbA1c at 52 Weeks in Insulin-Naïve T2D Patients (Pts) Treated with Oral Antihyperglycemic Medications (OAMs): IMAGINE 2 |
| 2014-09-04 | Eli Lilly and Company | Results Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes lilly.com ↗
Notably, patients in IMAGINE-1 continued treatment beyond 26 weeks, and the HbA1c superiority for BIL was maintained at 52 and 78 weeks. |
| 2014-06-14 | Eli Lilly and Company | Results Lilly's Basal Insulin Peglispro Shows Novel Mechanism of Action lilly.com ↗
When BIL and insulin glargine were each administered to achieve complete suppression of glucose production, which principally comes from the liver, BIL showed less activity in peripheral tissues, such as muscle and fat, than insulin glargine. |
| 2014-05-12 | Eli Lilly and Company | Results Lilly's Basal Insulin Peglispro Shows Superiority in HbA1c Reduction Compared to Insulin Glargine in Three Phase III Trials in Patients with Type 2 Diabetes lilly.com ↗
INDIANAPOLIS, May 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatment for both type 1 and type 2 diabetes. |
| 2013-09-17 | Eli Lilly and Company | Results Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting lilly.com ↗
LY2605541 exhibits a flatter glucodynamic profile than insulin glargine at steady state in subjects with type 1 diabetes |
| 2013-06-22 | Eli Lilly and Company | Results Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541 lilly.com ↗
The analysis provides more in-depth information about the reductions in required prandial (mealtime) insulin in LY2605541-treated patients compared to those treated with insulin glargine. |
| 2012-10-02 | Eli Lilly and Company | Results Lilly and Boehringer Ingelheim Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue lilly.com ↗
In addition to the reduction in nocturnal hypoglycaemia in LY2605541-treated patients, results showed the treatments had similar overall rates of hypoglycaemia (p=0.08, not statistically significant). |
| 2012-09-24 | Eli Lilly and Company | Results Data from Boehringer Ingelheim and Lilly showcase strength of Diabetes Alliance at EASD Annual Meeting lilly.com ↗
Novel long-acting basal insulin analog LY2605541 significantly reduces nocturnal hypoglycemia and fear of hypoglycemia compared to insulin glargine in patients with type 2 diabetes mellitus |
| 2012-06-11 | Eli Lilly and Company | Results Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine lilly.com ↗
Results of the type 1 diabetes study showed that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than insulin glargine. |
All press releases naming this drug 13 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin peglispro | “Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited. This...” PMID 29167192 ↗ Nov 20179“Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods.” NCT01925989 ↗ |
| Known as | BIL | “Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited. This...” PMID 29167192 ↗ Nov 2017 |
| Known as | Insulina peglispro | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108569 ↗ |
| Known as | Insuline peglispro | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108569 ↗ |
| Known as | LY2605541 | “Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods.” NCT01925989 ↗17“A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus” NCT02106364 ↗ |
| Action | Activate | “Insulin receptor agonist” CHEMBL2108569 ↗ |
| Modality | Protein / enzyme biologic | “novel long-acting basal insulin analog LY2605541” PMID 24198302 ↗ Nov 2013 |
| Route | Subcutaneous | “subcutaneous injection of LY2605541” NCT01027871 ↗ |
| Target | INSR | “Insulin receptor agonist” CHEMBL2108569 ↗ |